<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03434483</url>
  </required_header>
  <id_info>
    <org_study_id>FIBHGM-MIGATER</org_study_id>
    <secondary_id>PIE 16/00055</secondary_id>
    <nct_id>NCT03434483</nct_id>
  </id_info>
  <brief_title>The Microbiome as a Target for Precision Medicine in Atherosclerosis</brief_title>
  <acronym>MIGATER</acronym>
  <official_title>Microbiome, Inflammation and Genetics as a Target for Precision Medicine in AThERosclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital General Universitario Gregorio Marañon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundación para la Investigación Biomédica del Hospital Gregorio Maranon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital General Universitario Gregorio Marañon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cardiovascular diseases are the main cause of death in industrialized countries. Among them,
      atherosclerosis has the highest prevalence and constitutes a common pathological pathway
      responsible for the majority of cases of chronic ischemic heart disease, acute myocardial
      infarction, heart failure and cerebrovascular disease. Classic studies have confirmed
      well-established etiopathogenic factors of atherosclerosis based on genetic and immunological
      components and environmental modifying agents such as diet and exercise. But in addition,
      recent experimental studies have shown that dysbiosis (alteration of the microbiota) may be
      an additional factor that participates in the onset and progression of atherosclerosis. The
      objective of this study is to identify the potential interactions between changes in the
      microbiota, changes in the immune status, the clinical evolution and the instability and
      progression of atherosclerosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will prospectively study two groups of patients : 1) patients with acute coronary
      syndrome and 2) age and sex matched patients with chronic stable documented atherosclerosis.

      Immune cell populations and immune-related metabolites will be characterized, the genetic
      profile of the main known functional variants will be determined, and the oral,
      gastrointestinal, and blood microbiota will be compared in both groups in a transversal
      observational design.

      In addition, 1-year clinical follow-up will be performed and correlation with the evolution
      of the microbiota and immune response in a longitudinal design will be conducted.

      Besides, an angiographic substudy, for those patients included in the study but that require
      revascularization of culprit artery according to clinical indication, will be 1 year
      follow-up and functional assessment and intravascular imaging and the degree of remodelling
      of the atherosclerotic plaque will be correlated with the evolution of the microbiota and
      immune response in a longitudinal design.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 25, 2018</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Change from baseline in clinical evaluation at 12 months</measure>
    <time_frame>Inclusion, 1 week, 1 month, 3 months, 6 months and 12 months</time_frame>
    <description>Cardiac events register including hemostasis and biochemical determinations</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in fibrous cap thickness at 12 months</measure>
    <time_frame>Inclusion and 12 months</time_frame>
    <description>Angiographic substudy-Change from baseline in the thickness of the fibrous cap (μm) of an atherosclerotic plaque in the nonculprit vessel as measured using optical coherence tomography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Endothelial dysfunction</measure>
    <time_frame>Inclusion and 12 months</time_frame>
    <description>Angiographic substudy-Micro and macrovascular endothelial function measured using a Doppler pressure guidewire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intestinal microbiota composition changes 16S</measure>
    <time_frame>Inclusion, 1 week, 1 month, 3 months, 6 months and 12 months</time_frame>
    <description>Changes from baseline in intestinal microbiota will be analysed using the 16S rRNA target gene sequencing approach at 1 week, 1 month, 3 months, 6 months and 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intestinal microbiota composition changes metagenome</measure>
    <time_frame>Inclusion, 1 week, 1 month, 3 months, 6 months and 12 months</time_frame>
    <description>Changes from baseline in intestinal microbiota will be analysed using the metagenome sequencing approach at 1 week, 1 month, 3 months, 6 months and 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood microbiota composition changes 16S</measure>
    <time_frame>Inclusion, 1 week, 1 month, 3 months, 6 months and 12 months</time_frame>
    <description>Changes from baseline in blood microbiota will be analysed using the 16S rRNA target gene sequencing approach at 1 week, 1 month, 3 months, 6 months and 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood microbiota composition changes metagenome</measure>
    <time_frame>Inclusion, 1 week, 1 month, 3 months, 6 months and 12 months</time_frame>
    <description>Changes from baseline in blood microbiota will be analysed using the metagenome sequencing approach at 1 week, 1 month, 3 months, 6 months and 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral microbiota composition changes 16S</measure>
    <time_frame>Inclusion, 1 week, 1 month, 3 months, 6 months and 12 months</time_frame>
    <description>Changes from baseline in oral microbiota will be analysed using the 16S rRNA target gene sequencing approach at 1 week, 1 month, 3 months, 6 months and 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral microbiota composition changes metagenome</measure>
    <time_frame>Inclusion, 1 week, 1 month, 3 months, 6 months and 12 months</time_frame>
    <description>Changes from baseline in oral microbiota will be analysed using the genome sequencing approach at 1 week, 1 month, 3 months, 6 months and 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adaptive immune system status changes</measure>
    <time_frame>Inclusion, 1 week, 1 month, 3 months, 6 months and 12 months</time_frame>
    <description>Changes from baseline of adaptive immune cell lineages will be assessed dynamically using high performance cytometry at 1 week, 1 month, 3 months, 6 months and 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Innate immune system status changes</measure>
    <time_frame>Inclusion, 1 week, 1 month, 3 months, 6 months and 12 months</time_frame>
    <description>Changes from baseline of innate immune cell lineages will be assessed dynamically using high performance cytometry at 1 week, 1 month, 3 months, 6 months and 12 months</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <condition>Atherosclerosis</condition>
  <arm_group>
    <arm_group_label>Acute Coronary Syndrome</arm_group_label>
    <description>Patients with an episode of acute coronary syndrome. Clinical evaluation 1 year. Gene variants in atherosclerosis. Microbiota analysis. Immunological analysis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACS-Angiographic substudy</arm_group_label>
    <description>Patients included in the Acute Coronary Syndrome group with clinical indication for revascularization.
Clinical evaluation. Assessment of the atherosclerotic plaque in a moderate lession at baseline and 1-year .
Gene variants in atherosclerosis. Microbiota analysis. Immunological analysis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chronic coronary atherosclerosis</arm_group_label>
    <description>Patients with chronic atherosclerosis. Gene variants in atherosclerosis. Microbiota analysis. Immunological analysis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Assessment of the atherosclerotic plaque in a moderate lession.</intervention_name>
    <description>In patients who have been successfully revascularized the artery responsible for AMI and also present an intermediate lesion (40-80%) in another coronary territory, the clinical care protocol of the Cardiology Service stipulates the need for a physiological assessment with guidance of pressure (FFR).
The thickness of the fibrous cap shall be measured using optical coherence tomography.
In addition to the FFR measurement, a complete physiological assessment with a Doppler-pressure guide. This will allow the procedure to be performed without additional risk to the patient. The physiological study will include the analysis of endothelium-dependent vascular function and endothelium-independent vascular function.</description>
    <arm_group_label>ACS-Angiographic substudy</arm_group_label>
    <other_name>Coronary blood collection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Gene variants in atherosclerosis</intervention_name>
    <description>From the blood samples of the patients, the total DNA will be extracted and the main functional variants identified in the literature will be genotyped</description>
    <arm_group_label>ACS-Angiographic substudy</arm_group_label>
    <arm_group_label>Acute Coronary Syndrome</arm_group_label>
    <arm_group_label>Chronic coronary atherosclerosis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Microbiota analysis</intervention_name>
    <description>From the samples of blood, feces, oral cavity and blood, the DNA of the microbiota will be extracted using specific extraction kits and the microbiome will be analyzed through the study of 16S ribosomal RNA amplicons.</description>
    <arm_group_label>ACS-Angiographic substudy</arm_group_label>
    <arm_group_label>Acute Coronary Syndrome</arm_group_label>
    <arm_group_label>Chronic coronary atherosclerosis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Immunological analysis</intervention_name>
    <description>A study of immunological cell populations and cytokines will be carried out from fresh blood samples using antibody panels and flow cytometry</description>
    <arm_group_label>ACS-Angiographic substudy</arm_group_label>
    <arm_group_label>Acute Coronary Syndrome</arm_group_label>
    <arm_group_label>Chronic coronary atherosclerosis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Clinical evaluation</intervention_name>
    <description>Clinical evaluation including hemostasis and biochemical studies and questionaries for diet and exercice registration</description>
    <arm_group_label>ACS-Angiographic substudy</arm_group_label>
    <arm_group_label>Acute Coronary Syndrome</arm_group_label>
    <arm_group_label>Chronic coronary atherosclerosis</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Feces, blood, salive
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Acute coronary syndrome candidates for the study will be all patients with an episode of
        acute coronary syndrome wwho enter the Gregorio Marañón General University Hospital who
        meet all of the inclusion criteria and none of the exclusion criteria.

        Chronic atherosclerosis candidates for the study will be all patients with chronic
        atherosclerosis under follow-up in the General University Hospital Gregorio Marañón that
        meet all the following inclusion criteria and none of the exclusion criteria.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria Acute coronary syndrome group:

          -  Diagnosis of acute coronary syndrome

          -  Signature of informed consent for the study (Annex I).

        Exclusion Criteria Acute coronary syndrome group:

          -  Previous Ejection fraction of VI less than 30%.

          -  History of heart failure

          -  Systemic inflammatory diseases

          -  In treatment with corticosteroids or immunomodulators

          -  In treatment with antibiotics during the last month

        Aditional Inclusion Criteria for angiographic substudy group:

          -  Clinical indication of coronary angiography in the acute phase (in the first 72 hours
             after its hospital diagnosis).

          -  At least one non-causal coronary lesion in a coronary segment with reference diameter&gt;
             2 mm, stenosis between 40-80%, and TIMI 3 flow in this vessel (angiographic criteria,
             only confirmed after performing coronary angiography)

          -  Signature of informed consent for the substudy (Annex II).

        Aditional Exclusion Criteria for angiographic substudy group:

          -  Renal insufficiency with creatinine clearance less than 30 ml / h

          -  Hepatic insufficiency: patients with cirrhosis in Child B or C stages will be
             excluded.

        Inclusion Criteria Chronic atherosclerosis group:

          -  Angiographic diagnosis, using catheterization or computed tomography of coronary
             atherosclerotic disease.

          -  Clinical situation of stable chronic ischemic heart disease.

          -  Signature of informed consent for the study (Annex III).

        Exclusion Criteria Chronic atherosclerosis group:

          -  Previous Ejection fraction of VI less than 30%.

          -  History of heart failure

          -  Systemic inflammatory diseases

          -  In treatment with corticosteroids or immunomodulators

          -  In treatment with antibiotics during the last month
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francisco Fernández-Aviles, Prof, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital General Universitario Gregorio Marañón</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Javier Bermejo, MD, PhD</last_name>
    <phone>34915868279</phone>
    <email>javier.bermejo@salud.madrid.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Raquel Yotti, MD, PhD</last_name>
    <phone>34915868279</phone>
    <email>raquel.yotti@salud.madrid.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Maranon</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Javier Bermejo, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Raquel Yotti, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>January 8, 2018</study_first_submitted>
  <study_first_submitted_qc>February 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2018</study_first_posted>
  <last_update_submitted>August 21, 2018</last_update_submitted>
  <last_update_submitted_qc>August 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital General Universitario Gregorio Marañon</investigator_affiliation>
    <investigator_full_name>Javier Bermejo Thomas</investigator_full_name>
    <investigator_title>MD PhD Cardiology Department HGUGM</investigator_title>
  </responsible_party>
  <keyword>Microbiota</keyword>
  <keyword>Immunity</keyword>
  <keyword>Genetics</keyword>
  <keyword>Atherosclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

